一种用于管理源自食用动物的抗菌药物耐药性风险的线性模型。

A linear model for managing the risk of antimicrobial resistance originating in food animals.

作者信息

Bartholomew Mary J, Vose David J, Tollefson Linda R, Travis Curtis C

机构信息

FDA Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855, USA.

出版信息

Risk Anal. 2005 Feb;25(1):99-108. doi: 10.1111/j.0272-4332.2005.00570.x.

DOI:10.1111/j.0272-4332.2005.00570.x

PMID:15787760

Abstract

A linear population risk model used by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) estimates the risk of human cases of campylobacteriosis caused by fluoroquinolone-resistant Campylobacter. Among the cases of campylobacteriosis attributed to domestically produced chicken, the fluoroquinolone resistance is assumed to result from the use of fluoroquinolones in poultry in the United States. Properties of the linear population risk model are contrasted with those of a farm-to-fork model commonly used for microbial risk assessments. The utility of the linear population model for the purpose for which it was used by CVM is discussed.

摘要

美国食品药品监督管理局（FDA）兽药中心（CVM）使用的线性群体风险模型，估算了由耐氟喹诺酮弯曲杆菌引起人类弯曲杆菌病病例的风险。在家禽生产的鸡肉所导致的弯曲杆菌病病例中，耐氟喹诺酮特性被认为是美国禽类使用氟喹诺酮类药物所致。线性群体风险模型的特性与微生物风险评估中常用的从农场到餐桌模型的特性形成对比。文中讨论了CVM使用的线性群体模型在其应用目的方面的效用。